Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
=== In film === Several movies deal with rabies vaccine, notably the 1936 The Story of Louis Pasteur, which focuses on the life and achievements of Louis Pasteur, played by Paul Muni. The 1966 film Rage features a man bitten by a rabid dog who engages in a race against time to reach the nearest medical establishment to get the vaccine.
According to one of Liu's generals, education would make it so that “within ten to twenty years, the people will have forgotten even the names of the minority groups.” He established several schools for Tibetans in the borderlands in order to facilitate "Han-Tibetan language exchange". The language of instruction within schools was a matter of much debate within the provincial government, but by 1942, Liu's administration began prioritizing bilingual education in order to encourage Tibetans to learn Chinese. This came along with a slate of other measures aimed at creating a mobile educational system using geshe or khenpo monks to disseminate nationalist values to isolated and nomadic borderland communities. Liu recognized that the monks and lamas held more power in many areas of Xikang than the government; thus, the government would have to co-opt them. As part of this effort, anti-Japanese war propaganda and bilingual newspapers were posted on the walls of temples. Liu Wenhui criticized the Sinicization policies of past Xikang ruler Zhao Erfeng for being "extremist", saying that Zhao "emphasized force and acted too hastily"; however, this must be placed in light of his own contradictory stances.
Clinical trials are only a small part of the research that goes into developing a new treatment. Potential drugs, for example, first have to be discovered, purified, characterized, and tested in labs (in cell and animal studies) before ever undergoing clinical trials. In all, about 1,000 potential drugs are tested before just one reaches the point of being tested in a clinical trial. For example, a new cancer drug has, on average, six years of research behind it before it even makes it to clinical trials. But the major holdup in making new cancer drugs available is the time it takes to complete clinical trials themselves. On average, about eight years pass from the time a cancer drug enters clinical trials until it receives approval from regulatory agencies for sale to the public. Drugs for other diseases have similar timelines. Some reasons a clinical trial might last several years:
Sources: en.wikipedia.org
In September 2023, the UK's National Institute for Heath and Care Excellence (NICE) published guidance that it would not recommend Trastuzumab deruxtecan, to be used for treatment HER2 LOW breast cancer by the UK's National Heath Service (NHS), citing the cost of the drug being too high in comparison to its benefits. After talks with drug manufacturers AstraZeneca and Daiichi Sankyo, the NHS failed to negotiate a supply at what it deemed to be an acceptable price, and announced in March 2024 that the treatment would not be available to NHS patients. Roughly 1000 patients in the UK would have qualified for free treatment, had a supply been negotiated. Enhertu was however approved by The Scottish Medicines Consortium for use by NHS Scotland in December 2023. Trastuzumab deruxetecan remains funded for patients with HER2 positive advanced breast cancers.
Amino acid composition, and the limiting amino acid, which is usually lysine Preparation (cooking) Vitamin and mineral content Amino acid composition is the principal effect. All proteins are made up of combinations of the 21 biological amino acids. Some of these can be synthesised or converted in the body, whereas others cannot and must be ingested in the diet. These are known as essential amino acids (EAAs), of which there are 9 in humans. The number of EAAs varies according to species (see below). EAAs missing from the diet prevent the synthesis of proteins that require them. If a protein source is missing critical EAAs, then its biological value will be low as the missing EAAs form a bottleneck in protein synthesis. For example, if a hypothetical muscle protein requires phenylalanine (an essential amino acid), then this must be provided in the diet for the muscle protein to be produced. If the current protein source in the diet has no phenylalanine in it the muscle protein cannot be produced, giving a low usability and BV of the protein source. In a related way if amino acids are missing from the protein source which are particularly slow or energy consuming to synthesise this can result in a low BV. Methods of food preparation also affect the availability of amino acids in a food source. Some of food preparation may damage or destroy some EAAs, reducing the BV of the protein source. Many vitamins and minerals are vital for the correct function of cells in the test organism.
=== Configuration and wing === All-metal low-wing land monoplane with four wing-mounted low-bypass turbofan engines. Cantilever three-spar structure of modified trapezoid planform. Centre section integral with fuselage. Inboard sections, outboard sections and detachable leading and trailing edges. High-lift devices comprise full-span six-segment leading edge slats (contiguous at engine pylons) at up to 17.5% of chord (drooping to 35°), two-segment fixed-vane double-slotted trailing edge flaps occupying some 75% of the span (deploying to 40°) and five-segment spoilers (outboards used as spoilerons at high speeds, inboards used as lift dumpers on the ground). Two-segment outboard ailerons for low speed roll control. Boundary layer fences over pylons. Engines suspended from the wing on pylons act as anti-flutter weights. Trim range is 16–33% of mean aerodynamic chord.
== Discovery == Catch bonds were first proposed in 1988 in the Proceedings of the Royal Society by M. Dembo et al. while at Los Alamos National Laboratory. While developing molecular model to study the critical tension required to detach a membrane bound to a surface through adhesion molecules, it was found that it is theoretically possible for bond dissociation to be increased by force, decreased by force, and independent of force. The terms "slip bond", "catch bond", and "ideal bond" were coined by Dembo to describe these three types of bond behaviors. Slip bonds represent the ordinary behavior originally modeled by G. Bell, Dembo's former postdoctoral mentor at Los Alamos National Laboratory in 1978. Slip bonds were supported by flow chamber experiments where forces are applied on molecular bonds linking cells to chamber floor under shear flow. By comparison, no decisive evidence of catch bonds was found until 2003. This is due to experimental conditions that were unfavorable for detecting catch bonds, as well as the counterintuitive nature of the bonds themselves. For example, most early experiments were conducted in 96 well plates, an environment that does not provide any flow. Some experiments failed to produce shear stress that is now known to be critical to lengthen the lifetimes of catch bonds, while other experiments conducted under flow conditions too weak or too strong for optimal shear-induced strengthening of these bonds.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.